Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

P8828

Sigma-Aldrich

Pergolide mesylate salt

≥98%, solid

Sinonimo/i:

8β-[(Methylthio)methyl]-6-propylergoline methanesulfonate salt, Pergolide methanesulfonate salt

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C19H26N2S · CH4O3S
Numero CAS:
66104-23-2
Peso molecolare:
410.59
Numero MDL:
MFCD00153859
Codice UNSPSC:
12352200
ID PubChem:
24277927
NACRES:
NA.77

Saggio

≥98%

Stato

solid

Attività ottica

[α]20/D −35°, c = 0.2 in pyridine(lit.)

Colore

white

Solubilità

ethanol: 2 mg/mL
DMSO: 5.2 mg/mL
H2O: insoluble

Ideatore

Valeant

Temperatura di conservazione

−20°C

Stringa SMILE

CS(O)(=O)=O.[H][C@@]12Cc3c[nH]c4cccc(c34)[C@@]1([H])C[C@@H](CSC)CN2CCC

InChI

1S/C19H26N2S.CH4O3S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21;1-5(2,3)4/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3;1H3,(H,2,3,4)/t13-,16-,18-;/m1./s1
UWCVGPLTGZWHGS-ZORIOUSZSA-N

Informazioni sul gene

human ... DRD1(1812) , DRD2(1813) , DRD3(1814) , DRD4(1815) , DRD5(1816)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Azioni biochim/fisiol

Dopaminergic agonist; suppresses pituitary secretion of prolactin; anti-Parkinsonian agent.

Caratteristiche e vantaggi

This compound was developed by Valeant. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pittogrammi

Skull and crossbones
GHS06

Avvertenze

Danger

Indicazioni di pericolo

H300

Consigli di prudenza

P264 - P301 + P310

Classi di pericolo

Acute Tox. 2 Oral

Codice della classe di stoccaggio

6.1B - Non-combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
SLBM6092V
SLBF6838V
070M2011V
070M2011
119K1638

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Dianne McFarlane
The Veterinary clinics of North America. Equine practice, 27(1), 93-113 (2011-03-12)
Equine pituitary pars intermedia dysfunction (PPID), also known as equine Cushing's syndrome, is a widely recognized disease of aged horses. Over the past two decades, the aged horse population has expanded significantly and in addition, client awareness of PPID has
Kamal S Bhatia et al.
Behavioural brain research, 223(1), 227-232 (2011-05-17)
Psychostimulant abuse represents a psychiatric disorder and societal concern that has been largely unamenable to therapeutic interventions. We have previously demonstrated that the 5-HT₃ antagonist ondansetron or non-selective 5-HT(₂A/₂C) antagonist ketanserin administered 3.5 h following daily pergolide, a non-selective DA
Hans C Lou et al.
Journal of vision, 11(2), doi:10-doi:10 (2011-02-25)
Liberal acceptance, overconfidence, and increased activity of the neurotransmitter dopamine have been proposed to account for abnormal sensory experiences, for instance, hallucinations in schizophrenia. In normal subjects, increased sensory experience in Yoga Nidra meditation is linked to striatal dopamine release.
P Barone et al.
Neurology, 53(3), 573-579 (1999-08-17)
To determine whether pergolide monotherapy provides symptomatic relief in early PD. Early treatment with dopamine agonists may reduce the risk of motor fluctuations, which are most likely linked to levodopa therapy. Pergolide, a D1-D2 dopamine agonist, has been studied as
Nathan Silver et al.
Sleep medicine, 12(5), 440-444 (2011-01-18)
Restless legs syndrome (RLS) is a chronic disease, which is managed with palliative medications that are likely to be required for a patient's lifetime. It is, therefore, important to know the long-term consequences of these treatments. Currently, the most commonly
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.